Nanobiotix FY2024 EPS Estimate Boosted by Leerink Partnrs

Nanobiotix S.A. (NASDAQ:NBTX) – Research analysts at Leerink Partnrs raised their FY2024 EPS estimates for shares of Nanobiotix in a note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings per share of ($0.94) for the year, up from their prior forecast of ($1.22). The consensus estimate for Nanobiotix’s current full-year earnings is ($1.18) per share. Leerink Partnrs also issued estimates for Nanobiotix’s FY2025 earnings at ($0.51) EPS and FY2026 earnings at $0.84 EPS.

Separately, UBS Group raised shares of Nanobiotix to a “hold” rating in a research note on Monday, February 17th.

Nanobiotix Price Performance

Shares of NASDAQ:NBTX opened at $3.73 on Friday. The firm has a fifty day moving average of $3.49 and a two-hundred day moving average of $3.93. Nanobiotix has a 12-month low of $2.76 and a 12-month high of $7.51.

Institutional Investors Weigh In On Nanobiotix

Institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC bought a new position in shares of Nanobiotix during the 4th quarter valued at $29,000. Millennium Management LLC bought a new position in shares of Nanobiotix during the 4th quarter valued at $39,000. Jane Street Group LLC bought a new position in shares of Nanobiotix during the 4th quarter valued at $73,000. Finally, OLD Mission Capital LLC bought a new position in shares of Nanobiotix during the 4th quarter valued at $139,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.